<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193696</url>
  </required_header>
  <id_info>
    <org_study_id>RT+PD-1-HCC</org_study_id>
    <nct_id>NCT04193696</nct_id>
  </id_info>
  <brief_title>RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)</brief_title>
  <official_title>Combining Radiation Therapy With Anti-PD-1 for Patients With Advanced Hepatocellular Carcinoma (RT+PD-1-HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to
      increase in many countries in coming decades. Approximately 70-80% of newly diagnosed HCC
      patients already have advanced disease. Sorafenib and lenvatinib are recommended as
      first-line options for advanced HCC, the median overall survival of the patients with
      advanced HCC receiving sorafenib reached 10.7 months. Based on the results of phase II
      clinical studies and the recommendation of guidelines, the PD-1 monoclonal antibody, such as
      nivolumab and pembrolizumab, have been approved to treat the patients with advanced HCC by
      the FDA. PD-1 monoclonal antibody has been recommended as a second-line therapeutic strategy
      for HCC in the 2018 CSCO guidelines for the diagnosis and treatment of primary liver cancer.
      However, the results of existing studies indicate that the objective response rate (ORR) of
      first-line PD-1 antibody therapy for patients with advanced liver cancer is about 20%.

      There is a growing recognition of radiation-induced cancer cells-external tumor control
      mechanisms, in which radiation therapy(RT) contributes not only to local control of target
      lesions, but also to the control of metastases away from the treatment site. In recent years,
      RT combined with immunotherapy as a new treatment method has achieved certain curative effect
      in some patients with metastatic cancer. Therefore, it is interesting to investigate the
      efficacy of combining radiation therapy plus systemic anti-PD-1 immunotherapy for patients
      with advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This stuy has only one arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abscopal effects rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>radiotherapy plus PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma</intervention_name>
    <description>The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.</description>
    <arm_group_label>radiotherapy plus PD-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70 years

          -  Diagnosis of advanced HCC was confirmed by histopathological examination or clinical
             diagnosis, consistent with the following two conditions:

               1. Extrahepatic metastasis with more than one measurable lesion;

               2. Intrahepatic multifocal lesions with more than one measurable lesion independent
                  of the radiosurgery field

          -  Patients have Child-Pugh A liver function

          -  Expected survival ≥ 3 months

          -  Unwilling to receive or unable to tolerate first-line treatment with sorafenib

        Exclusion Criteria:

          -  History of other malignancy

          -  History of systemic immunotherapy

          -  History of Radiation therapy within 6 months before the first administration

          -  History of active autoimmune diseases requiring systemic treatment within 2 years
             before recruiting.

          -  There are active infections that require systemic treatment

          -  Any condition that is unstable or which could jeopardize the safety of the patient and
             his/her compliance in the study

          -  Pregnant or breast-feeding patients

          -  Diagnosed with immunodeficiency or receiving systemic glucocorticoid therapy or any
             other form of immunosuppressive therapy within 7 days before the first administration
             of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bang-De Xiang, MD</last_name>
    <phone>86-771-5330855</phone>
    <email>xiangbangde@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian-Xu Li, MD</last_name>
    <phone>86-771-5330855</phone>
    <email>lijianxu1236@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.</citation>
    <PMID>18650514</PMID>
  </reference>
  <reference>
    <citation>Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.</citation>
    <PMID>19095497</PMID>
  </reference>
  <reference>
    <citation>Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440.</citation>
    <PMID>29875066</PMID>
  </reference>
  <reference>
    <citation>El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.</citation>
    <PMID>28434648</PMID>
  </reference>
  <reference>
    <citation>Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017 Jan;67(1):65-85. doi: 10.3322/caac.21358. Epub 2016 Aug 29. Review.</citation>
    <PMID>27570942</PMID>
  </reference>
  <reference>
    <citation>Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.</citation>
    <PMID>25754329</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Hong Zhong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>advanced HCC</keyword>
  <keyword>anti-PD-1</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

